CMPI says requirements under federal health care reform would deprive Americans of medical innovation worth trillions over 10 years
New York, NY (June 12, 2012) --- Personalized medicine – treatments targeting individual risk of disease -- can increase life expectancy and generate $13 trillion in health value – but comparative effectiveness research would reduce investment in such innovations according to a report released today by the Center for Medicine in the Public Interest (CMPI), entitled: “Promoting Innovation and Health: Personalized Medicine or Comparative Effectiveness Research?”
"Our analysis shows that personalized medicine can increase life, well-being and the social value of health but also demonstrates that CER increases the cost and uncertainty of investing in such innovation," said John A. Vernon, Ph.D., a professor at the Purdue University, Krannert School of Management and co-author of the study. "CER will deny our nation better health and much needed biomedical investment."
The federal health reform law requires government-run comparative-effectiveness research, which will purport to evaluate the costs and benefits of different treatment options -- and use these studies to decide what medical innovations government and health plans should pay for and to limit what technologies doctors and patients can choose.
Proponents of CER claim it can increase investment in personalized medicine. But the CMPI study, conducted for its Personalized Medicine Acceleration Working Group, found that CER will reduce the level of investment in biomedical research by $75 billion over 10 years. There would be 60 fewer new personalized medicines available over the next decade if CER is required before marketing.
“We need to build upon the promise of personalized medicine,” said Robert Goldberg, Ph.D., Vice President of CMPI and co-author of the study. “Commercialization of innovations that reduce cost and extend life contribute to our nation’s prosperity and our global competitiveness. Policymakers should find ways accelerate the adoption of personalized medicine rather than adding regulatory requirements that increase the cost and risk of innovation.”
The study was conducted for The Personalized Medicine Acceleration Working Group, a CMPI project focusing on actionable steps that can be taken to speed up the commercialization and adoption of personalized medicine. The study and the working group were supported with a grant from the Ewing Marion Kauffman Foundation (www.Kauffman.org)
The report -- "Uncertain Innovation: The Effect of Comparative Effectiveness Research (CER) On Personalized Medicine" -- can be downloaded here: http://cmpi.org/reports-newsletters/reports/uncertain-innovation
Reporters interested in scheduling an interview with the authors of the report should contact CMPI Vice President Bob Goldberg at firstname.lastname@example.org at 212-417-9169.
The Center for Medicine in the Public Interest, a non-profit public policy group dedicated to research-based free market reforms for the health care industry.